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1. Introduction
  Acute myocardial infarction (AMI) is one of the most fateful 
diseases in China[1]. With the development of cardiac 
intervention therapy, percutaneous coronary intervention 
(PCI) has become a crucial treatment to restore the blood 
flow in early stage[2]. However, there are still 10%-30% of 
the patients that suffer ischemia-reperfusion injury (IRI) 
after PCI treatment. Consequently, the size of myocardial 
infarction was expanded due to the apoptosis[3] and 
autophagy[4] caused by IRI. Therefore, discovering more 
effective drugs for reducing ischemia-reperfusion injury 
and keeping the vitality of myocardial cells is necessary.
  Interleukin-6 (IL-6) was originally identified as B-cell 
stimulatory factor 2 that promotes immunoglobulin 
synthesis by activated B cells[5]. IL-6 is not expressed in 
healthy persons, but when infections or tissue injuries 
occur, IL-6 is rapidly synthesized and contributes to host 
defense[6]. However, excessive production of IL-6 during 
this process has been implicated in the development 
of acute, severe complications, including systemic 
inflammatory response syndrome (SIRS) and cytokine-
release syndrome (CRS)[7]. Recent studies showed that 
the expression of IL-6 and its receptor was significantly 
increased during Acute myocardial ischemia-reperfusion 
(AMI/R) period and appeared a prognostic relevance 
for patients who experienced AMI[8]. Tocilizumab(Trade 
name: ACTEMRA@) is a humanized monoclonal antibody 
directed against interleukin-6 receptor. The molecule 
was humanized by the grafting of the complementarity-
determining regions of a mouse anti-human IL-6 receptor 
mAb onto human IgG1. It inhibits the binding of IL-6 to its 
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receptors, and thus reduces the cytokines pro-inflammatory 
activity by competing for both the soluble and membrane-
bound forms of the human IL-6 receptor[9]. Tocilizumab is 
marketed in Japan for Castleman disease and several types 
of arthritis[10,11]. In the European Union, the product is 
approved for treatment of moderate-to-severe rheumatoid 
arthritis[12]. However, the functions and molecular 
mechanisms of tocilizumab for protection myocardial cells 
ischemia-reperfusion injury after AMI are still poorly 
understood.
  In this study, we demonstrated that tocilizumab displayed 
a protective effect for human cardiac myocytes after 
ischemia-reperfusion injury. Tocilizumab could suppress 
apoptosis and keep vitality of human cardiac myocytes after 
ischemia-reperfusion injury partly through down-regulating 
Bcl-2 and up-regulating Bax expression in vitro.
2. Materials and methods
2.1. Cell culture
  The human cardiac myocytes were obtained from the 
ScienCell Research Laboratories (Carlsbad, California, 
USA). Cells were cultured in complete Dulbecco’s modified 
Eagle medium (DMEM, Mediatech, USA) containing 10% 
fetal bovine serum (FBS, Gibco BRL, USA) in a humidified 
containing of 5% CO2 incubator at 37 曟. The logarithmic 
growth phase cells were harvested for further assays.
2.2. Tocilizumab intervention process
  The Tocilizumab (Roche, Switzerland) was diluted with 1
暳DMEM medium and adjusted the density of 1.0 mg/mL, 
3.0 mg/mL and 5.0 mg/mL, respectively. human cardiac 
myocytes were seeded in 6-well plates at the concentration 
of 1暳10
6/well, and divided into four groups, describing 
as negative control group (NC Group, DMEM only), Test A 
group (Tocilizumab 1.0 mg/mL), Test B group (Tocilizumab 
3.0 mg/mL), Test C group (Tocilizumab 5.0 mg/mL). Cells 
were intervened with different densities of tocilizumab 
or DMEM, and cultured in a humidified containing 5% 
CO2 incubator at 37 曟. Cells were harvest after 24 h 
intervention, and then used for further experiments.
2.3. Establishment of model of acute ischemia and reperfusion 
of human cardiac myocytes 
  The simulated ischemia reagent and reperfusion reagent 
were prepared according to the manufacture, that Ross et 
al previously reported[13]. The intervened human cardiac 
myocytes were washed by PBS for twice. Cells were added 
with 3 mL simulated ischemia reagent and cultured in a 
humidified containing 5% CO2 and 95% N2 incubator at 37 曟 
for 24 h. 3 mL simulated reperfusion reagent was used to 
replace the simulated ischemia reagent, and cultured the 
cells in normal environment for 1 h.
2.4. MTT assay
  3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT, Roche, USA) assay was used to determine 
the proliferation viability. Cell viability was calculated at 24 
h, 48 h and 72 h after ischemia simulation and reperfusion 
intervention. The absorbance of the samples was measured 
using a model 550 microplate reader (Bio-Rad Laboratories, 
USA), at a wavelength of 490 nm. Three independent 
experimental replicates were performed.
2.5. Cell apoptosis detection
  Annexin-V-FLUOS Staining Kit (Roche, USA) was 
purchased to evaluate cell apoptosis after 48h intervention. 
Briefly, the samples were analyzed by BD FACS Canto 栻
Flow Cytometer (Becton Dickinson, USA). Three independent 
experimental replicates were performed.
2.6. qRT-PCR
 
  Total RNA was isolated from human cardiac myocytes, 
which underwent simulated ischemia and reperfusion 
in tervent ion ,  by  TRIZOL襆 reagent  ( Inv i t rogen, 
USA) according to the manufacturer. The following 
primers were synthesized: Bcl-2 sense primer 5’-
CCTTTGTGTAACTGTACGGCC-3’ and anti-sense primer 5’-
CTTTGGCAGTAAATAGCTGATTCGAC-3’, Bax sense primer 
5’-TCCACCAAGAAGCTGAGCGAG-3’ and anti-sense primer 
5’-GTCCAGCCCATGATGGTTCT- 3’, 毬-actin sense primer 
5’-CTCCATCCTGGCCTCGCTGT-3’ and anti-sense primer 
5’-GCTGTCACCTTCACCGTTCC -3’. Reverse transcription 
was performed by the RevertidTM First Strand cDNA Synthesis 
Kit (Fermentas, USA). Synthetized cDNA was amplified and 
quantified by Real-time PCR using SYBR襆 Premix Ex 
TaqTM 栻 (Tli RNaseH Plus, Takara, Japan). The human 毬
-actin gene was served as an internal control. Relative gene 
expression was calculated with the 2-吤吤Ct method. Three 
independent experimental replicates were performed.
2.7. Western blot assay
  Human anti-rabbit Bcl-2(SC-7382, Santa Cruz, USA) 
(1:1 000), Bax(SC-7480, Santa Cruz, USA) (1:1 000) and human 
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anti-mouse 毬-actin (Santa Cruz, USA) (1:5 000) antibodies 
were used for western blot assay. Secondary horseradish 
peroxidase-conjugated goat anti-mouse or -rabbit antibody 
(Bio-Rad, USA) were used at a 1:5 000 dilution. The relative 
protein concentration were measured by gray value, which 
was displayed by the Enhanced Chemiluminescence Regent 
(Millipore, USA). 
2.8. Statistic analysis
  All date are presented as (Mean暲SD). Two-tailed Student’s 
t test or ANOVA was used to evaluate statistical significant 
using GraphPad Prism 5 software (GraphPad Software, Inc). 
P<0.05 was considered as statistically significant different.
3. Results
3.1. Proliferation viability of tocilizumab intervened human 
cardiac myocytes after IRI
  Compared to the NC group, cells intervened by tocilizumab 
appeared a higher proliferation viability after underwent 
IRI in vitro (P<0.05). Moreover, a significant proliferation 
difference was observed between test A group and test B 
group (P<0.05), but not in test B group and test C group 
(P>0.05). Data was shown in Figure 1.
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Figure 1. Tocilizumab protects proliferation viability of human 
cardiac myocytes after AMI/R.
The relative cell proliferation rate of each group at different time 
points was determined by MTT assay. Cell proliferation curves were 
plotted. n=3. *P<0.05.
3.2. Apoptosis of tocilizumab intervened human cardiac 
myocytes after IRI
  As shown in Figure 2, tocilizumab could effectively 
protect human cardiac myocytes to resistance apoptosis 
caused by IRI in test groups compared to NC group 
(P<0.05). The medium concentration of tocilizumab (3 mg/
mL) could play a more effective apoptotic resistance than 
minimal concentration (1 mg/mL) (P<0.05), but there was no 
significant changes at a more higher concentration (5 mg/mL) 
(P>0.05).
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Figure 2. Tocilizumab inhibits apoptosis of human cardiac myocytes 
after AMI/R.
The cell apoptosis of each group was detected by flow cytometry. n=3. 
Data show representative results of repeat experiments. *P<0.05.
3.3. Expression changes of Bcl-2 and Bax in tocilizumab 
intervened human cardiac myocytes after IRI
  According to the results shown above, tocilizumab could 
keep proliferation viability and resist apoptosis of human 
cardiac myocytes after IRI. To investigate the possible 
molecular mechanisms, the mRNA and protein levels of 
Bcl-2 and Bax were detected, which were two classic genes 
in cell growth regulation, in each test or NC group cells 
by qRT-PCR and western blot. Both mRNA and protein 
levels of Bcl-2 were more significantly up-regulated in 
test groups than in NC group (P<0.05, Figure 3A and 3C), 
in the meanwhile, the expression levels of Bax were more 
significantly down-regulated in test groups than in NC group 
(P<0.05, Figure 3B and 3C). Furthermore, within the test 
groups, the mRNA and protein levels of Bcl-2 were higher, 
while Bax were lower, in 3 mg/mL group than in 1 mg/mL 
group (P<0.05), but there was no significant change between 
3 mg/mL group and 5 mg/mL group (P>0.05).
4. Discussion
  AMI is the most common complications of coronary heart 
disease. Recently, the incidence of AMI rises every year in 
our country. Restoring myocardial blood flow as quickly 
as possible is one of the most crucial process to improve 
the prognosis of AMI patients[14]. At the same time, how to 
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reduce or avoid the IRI becomes an overarching concern for 
all doctors. Nowadays, many of interleukins such as IL-1[15], 
IL-8[16], IL-10[17] and IL-17A[18], has been demonstrated to 
activate and participate in IRI of myocardium after AMI/R. 
IL-6 serve as an important factor in several inflammatory 
processes, and it can lead to a so called “waterfall effect” 
of inflammation[19], and eventually induce apoptosis and 
disintegration of certain cells. Recently, studies found that 
IL-6 of myocardium was significant elevated in IRI group 
compared to ischemic preconditioning group and positive 
associated with the infarct size in rat AMI/R model[20]. Zhao 
et al reported that atorvastatin could reduce myocardium 
necrosis area in a rabbit model of AMI/R through down-
regulating the serum IL-6 level[21]. These evidences suggest 
that IL-6 could serve as a therapeutic target to prevent IRI 
of myocardium. This led to the development of tocilizumab, 
a humanized monoclonal antibody, with the CDR of a mouse 
anti-IL-6R grafted on to human IgG1 molecule. Tocilizumab 
can block both classic and trans-signaling pathways by 
inhibiting IL-6 binding to transmembrane IL-6R and 
soluble IL-6R. 
  In this study, we treated human cardiac myocytes with 
different concentrations of tocilizumab, and detected the 
tolerance of human cardiac myocytes to AMI/R. Firstly, 
we used MTT assay to detect cell proliferation viability, 
and found that tocilizumab could prominently keep the 
proliferation activity of human cardiac myocytes after AMI/
R. Furthermore, the results of flow cytometry demonstrated 
that tocilizumab also could inhibit human cardiac myocytes 
apoptosis after AMI/R. Interestingly, we found that cells 
treated with 3 mg/mL tocilizumab could gain a better 
protective effect than 1mg/mL, but no more improvement 
when the concentration evaluate to 5 mg/mL. This means 
that the protective effect has a character of saturability, and 
the reason may be that the binding of antigen to antibody 
has reached saturation. In order to realize the molecular 
mechanisms of these effects, we detected two classic growth 
regulation genes, Bcl-2 and Bax. The expression of Bcl-2 
was up-regulation, while the expression of Bax was down-
regulation, in test groups compared to the NC group. In 
accordance with the functional results, these changes 
could be enlarged with the increasing concentrations 
of tocilizumab from 1 mg/mL to 3 mg/mL, but no more 
expansion observed when the concentrations of tocilizumab 
continuously increased to 5mg/mL. It has been proved that 
IL-6 combined with IL-6R could phosphorylate STAT1 to 
p-STAT1 in Ser-727 position, and p-STAT1 served as a co-
transactivator for enhancing the transcription of Bax[22,23]. 
Tocilizumab could competitive bind with IL-6R and block 
the phosphorylation of STAT1, then regulating the expression 
of Bax and Bcl-2. That may partly explain the results we 
obtained.
  In conclusion, tocilizumab could significantly suppress 
the apoptosis and keep the proliferation viability of human 
cardiac myocytes  after AMI/R.tocilizumab has wide 
application prospects in the protection of myocardium 
ischemia reperfusion 
Conflict of interest statement
  We declare that we have no conflict of interest.
References
[1]   Wang M, Moran AE, Liu J, Coxson PG, Heidenreich PA, Gu 
D, et al.. Cost-effectiveness of optimal use of acute myocardial 
infarction treatments and impact on coronary heart disease 
mortality in China. Circ Cardiovasc Qual Outcomes 2014; 
7(1):78-85.
[2]  Neskovic AN, Stankovic I, Milicevic P, Aleksic A, Vlahovic-
5
4
3
2
1
0R
el
at
iv
e 
ex
pr
es
si
on
 o
f B
cl
-
2 
m
R
N
A
A
NC Group
Test A Group
Test B Group
Test C Group
NC     1 mg/mL  3 mg/mL  5 mg/mL
Tocillizumab (mg/mL)
1.2
1.0
0.8
0.6
0.4
0.2
0.0R
el
at
iv
e 
ex
pr
es
si
on
 o
f B
ax
 m
R
N
A
B
NC Group
Test A Group
Test B Group
Test C Group
NC     1 mg/mL  3 mg/mL  5 mg/mL
Tocillizumab (mg/mL)
Bcl-2
Bax
毬-actin
C
NC                  1.0 mg/mL         3.0 mg/mL     5.0 mg/mL
Figure 3. Tocilizumab regulates the expression of Bcl-2 and Bax in human cardiac myocytes after AMI/R.
The Bcl-2 (A) and Bax (B) mRNA levels of each group were determined by qRT-PCR. n=3. Data show representative results of repeat 
experiments. *P<0.05. The Bcl-2and Bax protein levels of each group were determined by western blot (C).
Xi Lin et al./Asian Pacific Journal of Tropical Medicine (2015)48-5252
Stipac A, Calija B, et al. Primary PCI for acute myocardial 
infarction in a patient with idiopathic thrombocytopenic purpura. A 
case report and review of the literature. Herz 2010; 35(1): 43-49. 
[3]  Liu Y, Yang H, Song L, Li N, Han QY, Tian C, et al. AGGF1 
protects from myocardial ischemia/reperfusion injury by regulating 
myocardial apoptosis and angiogenesis. Apoptosis 2014; 19(8): 
1254-1268.
[4]  Xu J, Qin X, Cai X, Yang L, Xing Y, Li J, et al. Mitochondrial 
JNK activation triggers autophagy and apoptosis and aggravates 
myocardial injury following ischemia/reperfusion. Biochim Biophys 
Acta 2014; S0925-4439(14): 140-149.
[5]  Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, 
immunity, and disease. Cold Spring Harb Perspect Biol 2014; 
6(10): a016295.
[6]  Savvatis K, M俟ller I, Fr觟hlich M, Pappritz K, Zietsch C, 
Hamdani N, et al. Interleukin-6 receptor inhibition modulates 
the immune reaction and restores titin phosphorylation in 
experimental myocarditis. Basic Res Cardiol 2014; 109(6): 449. 
[7]  Talebi-Taher M, Babazadeh S, Barati M, Latifnia M. Serum 
inflammatory markers in the elderly: are they useful in 
differentiating sepsis from SIRS. Acta Med Iran 2014; 52(6): 438-
442.
[8]  Ritschel VN, Seljeflot I, Arnesen H, Halvorsen S, Weiss T, 
Eritsland J, et al. IL-6 signalling in patients with acute ST-
elevation myocardial infarction. Results Immunol 2013; 14(4): 
8-13.
[9]  Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the 
interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012; 52: 
199-219.
[10] Shirakawa K, Egashira T, Ieda M, Kawaguchi S, Okamoto K, Kudo 
M, et al. Multidisciplinary approach to the treatment of cardiac 
AA amyloidosis and aortic stenosis due toCastleman’s disease: 
a hybrid therapy with tocilizumab and aortic valve replacement. 
Int J Cardiol 2014; 173(2): e9-e11.
[11] Nakajima T, Kawabata D, Nakabo S, Miyagawa-Hayashino 
A, Yukawa N, Yoshifuji H, et al. Successful treatment 
with tocilizumab in a case of intralymphatic histiocytosis 
associated with rheumatoid arthritis. Intern Med 2014; 53(19): 
2255-2258.
[12] Traki L, Rostom S, Tahiri L, Bahiri R, Harzy T, Abouqal R, et 
al. Responsiveness of the EuroQol EQ-5D and Hospital Anxiety 
and Depression Scale (HADS) inrheumatoid arthritis patients 
receiving tocilizumab. Clin Rheumatol 2014; 33(8): 1055-1060. 
[13] Ross JL, Howlett SE. Age and ovariectomy abolish beneficial 
effects of female sex on rat ventricular myocytes exposed to 
simulatedischemia and reperfusion. PLoS One 2012; 7(6): e38425.
[14] Shacham Y, Steinvil A, Leshem-Rubinow E, Assa EB, Keren 
G, Roth A, et al. Association between time to reperfusion and 
echocardiography assessed left ventricular filling pressure in 
patients with first ST-segment elevation myocardial infarction 
undergoing primary coronary intervention. Cardiol J 2014; 21(4): 
357-363.
[15] Grothusen C, Hagemann A, Attmann T, Braesen J, Broch O, 
Cremer J, et al. Impact of an interleukin-1 receptor antagonist and 
erythropoietin on experimental myocardial ischemia/reperfusion 
injury. Sci World J 2012; 2012: 737585.
[16] Kilgore KS, Park JL, Tanhehco EJ, Booth EA, Marks RM, 
Lucchesi BR. Attenuation of interleukin-8 expression in C6-
deficient rabbits after myocardial ischemia/reperfusion. J Mol Cell 
Cardiol 1998; 30(1):75-85.
[17] Markowski P, Boehm O, Goelz L, Haesner AL, Ehrentraut 
H, Bauerfeld K, et al. Pre-conditioning with synthetic CpG-
oligonucleotides attenuates myocardial ischemia/reperfusion 
injury via IL-10 up-regulation. Basic Res Cardiol 2013; 108(5): 
376.
[18] Liao YH, Xia N, Zhou SF, Tang TT, Yan XX, Lv BJ, et al. 
Interleukin-17A contributes to myocardial ischemia/reperfusion 
injury by regulating cardiomyocyte apoptosis and neutrophil 
infiltration. J Am Coll Cardiol 2012; 59(4): 420-429. 
[19] Volpin G, Cohen M, Assaf M, Meir T, Katz R, Pollack S. Cytokine 
levels (IL-4, IL-6, IL-8 and TGF毬) as potential biomarkers of 
systemic inflammatory response in trauma patients. Int Orthop 
2014; 38(6): 1303-1309.
[20] Zhang JQ, Wang Q, Xue FS, Li RP, Cheng Y, Cui XL, et 
al. Ischemic preconditioning produces more powerful anti-
inflammatory and cardioprotective effects than limb remote 
ischemic postconditioning in rats with myocardial ischemia-
reperfusion injury. Chin Med J (Engl) 2013; 126(20): 3949-3955.
[21] Zhao XJ, Liu XL, He GX, Xu HP. Effects of single-dose 
atorvastatin on interleukin-6, interferon gamma, and myocardial 
no-reflow in a rabbit model of acute myocardial infarction and 
reperfusion. Braz J Med Biol Res 2014; 47(3): 245-251.
[22] Chang CW,  Tsai WH,  Chuang WJ, Lin YS, Wu JJ, Liu CC, et 
al. Procaspase 8 and Bax are up-regulated by distinct pathways 
in streptococcal pyrogenic exotoxin B-induced apoptosis. J Biol 
Chem 2009; 284(48): 33195-33205.
[23] Kimura A, Naka T, Nakahama T, Chinen I, Masuda K, Nohara 
K, et al. Aryl hydrocarbon receptor in combination with Stat1 
regulates LPS-induced inflammatory responses. J Exp Med 2009; 
206(9): 2027-2035.
